April 17, 2012
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced yesterday that Dr.
, Ph.D., has been named as director of the Company's board of directors.
Since 2012, Dr. Weiner serves as Special Advisor to the Chief Executive Officer of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA, TASE: TEVA.TA). Dr. Weiner brings to XTL his vast experience in pharmaceutical development, from R&D to regulatory approval. Dr. Weiner has been with Teva for 36 years.
"I am very pleased to have joined XTL as member of the board of directors and I will use my R&D expertise in the product development of the Company," said Dr. Weiner.
Dr. Weiner received his Ph.D. in chemistry from the
Hebrew University of Jerusalem
, where he also earned B.Sc. and M.Sc. degrees, followed by a post-doctoral fellowship at Schering-Plough Corporation in
the United States
. He was granted the Rothschild Prize for Innovation/Export twice, in 1989 for the development of Alpha D3 for dialysis and osteoporosis, and in 1999 for the development of Copaxone® for multiple sclerosis.
, XTL's CEO commented "Dr. Weiner brings with him 40 years of drug development experience in the pharmaceutical industry, with large number of New Drug Application approvals under his leadership. We are very pleased that he joined our board, and believe his experience will be extremely valuable as we progress with our clinical development programs."
About XTL Biopharmaceuticals, Ltd. ("XTL")
XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.